Efficacy and Safety of TKI Plus PD-1 Inhibitors in Elderly uHCC Patients: A Retrospective Study

PURPOSE: To explore the efficacy and safety of sorafenib- or lenvatinib-based combination therapy with PD-1 inhibitors in elderly patients aged ≥75 years with unresectable hepatocellular carcinoma (uHCC). PATIENTS AND METHODS: Systemic therapy-naïve uHCC patients who received first-line sorafenib- o...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Bowen, Lei, Jin, Zhao, Haitao, Dong, Jinghui, Zeng, Zhen, Li, Yinyin, Yu, Lingxiang, Zhou, Lin, Jia, Aiying, Lu, Yinying, Cheng, Jiamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653036/
https://www.ncbi.nlm.nih.gov/pubmed/36389129
http://dx.doi.org/10.2147/JHC.S387254

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653036/
https://www.ncbi.nlm.nih.gov/pubmed/36389129
http://dx.doi.org/10.2147/JHC.S387254

Ejemplares similares